L-Histidine Boosts with Probiotics in Depression Study

observational-study PMID: 39271063

L-Histidine Boosts with Probiotics in Depression Study

Quick Summary: A study tested if a probiotic called Lactobacillus plantarum 299v (LP299v) could help people with major depression who are already taking antidepressant meds like SSRIs. The main finding was that this probiotic raised levels of L-histidine, an amino acid linked to brain health, while also improving other body chemicals tied to energy production and inflammation. These changes hint at how gut bacteria might support mental health.

What The Research Found

Researchers used special tests to check blood changes in people with depression. Adding the probiotic to standard treatment led to clear shifts in body chemicals. Here's what stood out:

Higher L-Histidine Levels: L-Histidine, a building block for proteins and brain chemicals, increased significantly in the probiotic group (p=0.013). This amino acid helps make histamine, which plays a role in mood and stress response.
Better Energy in Cells: Long-chain acylcarnitines dropped more in the probiotic group, pointing to improved mitochondrial function—the powerhouses in cells that could be sluggish in depression.
Less Inflammation Markers: N-acyl taurines fell over four times more than in the placebo group, suggesting the probiotic helps calm body-wide inflammation.
Other Positive Shifts: Levels of oxidized glycerophosphocholine (oxPC) and sphingomyelins rose, which may protect brain cells and stabilize mood by fighting oxidative stress and supporting cell membranes.
Bonus Changes: The probiotic also boosted D-valine (another amino acid) and p-cresol, linking gut bacteria to overall metabolic balance disrupted in depression.

These findings connect gut health to brain function, showing how probiotics might tweak metabolism to ease depression symptoms.

Study Details

Who Was Studied: 44 adults aged 18-65 with major depressive disorder (MDD), split evenly into two groups. All were on SSRI antidepressants for their depression.
How Long: Participants took the supplement daily for 8 weeks.
What They Took: The probiotic group got 1 billion colony-forming units (CFU) of LP299v each day in a powder form. The placebo group got a fake version that looked the same. Everyone kept their regular SSRI meds.

The study was double-blind and randomized, meaning neither participants nor researchers knew who got the real probiotic until the end. They analyzed blood samples with advanced tools to spot these chemical changes.

What This Means For You

If you're dealing with depression or know someone who is, this research suggests probiotics like LP299v could be a simple add-on to your antidepressant routine. L-Histidine's rise might support better mood by aiding neurotransmitter production and acting as an antioxidant to protect brain cells.

Gut-Brain Connection: Your gut bacteria influence your mental health—boosting good ones with probiotics may reduce inflammation and improve energy in your cells, potentially easing fatigue or brain fog in depression.
Practical Tip: Talk to your doctor before trying LP299v or any probiotic supplement, especially if you're on SSRIs. It might enhance your treatment, but results vary by person. Foods rich in L-histidine, like meat, fish, or beans, could also help maintain levels naturally.
Why It Matters: This isn't a cure, but it shows promise for personalized mental health care, linking diet, gut health, and meds for better outcomes.

Study Limitations

This was an early "exploratory" study with just 44 people, so it can't prove these changes work for everyone or fix depression on their own. They didn't directly measure mood improvements here—focusing instead on blood markers—and didn't adjust stats for multiple tests, which could mean some results are by chance. Long-term effects aren't known, and more research is needed to confirm how L-histidine and these shifts truly help with symptoms. Always view this as one piece of the puzzle, not medical advice.

Key Findings

The study found that supplementation with Lactobacillus plantarum 299v (LP299v) in patients with major depressive disorder (MDD) undergoing selective serotonin reuptake inhibitor (SSRI) therapy significantly elevated L-histidine levels (p=0.013) compared to placebo. LP299v also reduced long-chain acylcarnitines and N-acyl taurines more than placebo, suggesting improved mitochondrial function and reduced inflammation. Additionally, increases in oxidized glycerophosphocholine (oxPC) and sphingomyelins were observed. These changes align with potential mechanisms linking gut microbiota modulation to metabolic and cognitive improvements in MDD.

Study Design

This was a double-blind, randomized, placebo-controlled trial with a metabolomics secondary analysis. The study included 44 adults with MDD (22 in LP299v group, 22 in placebo group), aged 18–65, treated with SSRIs. Participants received either LP299v or placebo for 8 weeks. Metabolic profiling used LC-QTOF-MS, CE-TOF-MS, and chiral LC-QqQ-MS to analyze plasma samples.

Dosage & Administration

The LP299v group received 1×10⁹ colony-forming units (CFU)/day orally, administered as a freeze-dried supplement in identical packaging to the placebo. Both groups continued standard SSRI therapy. Supplementation was taken once daily for 8 weeks.

Results & Efficacy

L-histidine: LP299v increased plasma levels compared to placebo (p=0.013).
N-acyl taurines: LP299v reduced these metabolites 4.3-fold more than placebo, though exact p-values were not reported.
Sphingomyelins and oxPC: Both were elevated in the LP299v group, indicating potential anti-inflammatory and membrane-stabilizing effects.
Long-chain acylcarnitines: Decreased more in the LP299v group, suggesting enhanced mitochondrial fatty acid oxidation.
Statistical significance was set at p<0.05; confidence intervals were not explicitly reported.

Limitations

The study is exploratory, with a relatively small sample size (n=44), limiting generalizability. Metabolomics data were analyzed without correction for multiple comparisons, raising the risk of false positives. Clinical outcomes (e.g., depression severity) were not directly assessed here, as the focus was on biochemical changes. Causality between metabolic shifts and cognitive improvements (noted in prior work) remains unproven. Long-term effects of LP299v on these pathways were not evaluated.

Clinical Relevance

These findings suggest that LP299v supplementation may modulate metabolic pathways linked to mitochondrial function, inflammation, and gut-brain axis communication in MDD patients on SSRIs. The increase in L-histidine—a precursor for neurotransmitter synthesis and antioxidant activity—could support neuroprotection or mood regulation. However, the study does not establish clinical efficacy for depression symptoms; it highlights biochemical changes warranting mechanistic exploration. Supplement users should note that probiotics like LP299v may influence systemic metabolism but require further research to confirm therapeutic relevance. Combining probiotics with SSRIs might offer adjunctive benefits, but individual responses could vary.

Word count: ~380